What Are Analysts Talking About Cytokinetics (CYTK)?

Insider Monkey
28 Jan

We recently published a list of 10 Stocks That Analysts Are Talking About. In this article, we are going to take a look at where Cytokinetics, Incorporated (NASDAQ:CYTK) stands against other stocks that analysts are talking about.

Like any other informed investor, we are always on the hunt for stocks that analysts are talking about. Analysts use their in-depth research expertise, industry knowledge, and industry connections to figure out how well companies are doing every quarter.

Once they stumble upon something that could change the course of that company’s stock, they come out with analyst updates. These are usually in the form of an upgrade or downgrade, or simply an update on a previously assigned rating.

For retail investors, going through these reports saves a lot of time. This is why we came up with 10 stocks that analysts are talking about this week. To come up with the list of 10 stocks that analysts are talking about, we considered companies that received an analyst upgrade or coverage in the last 5 days.

A lab technician using a microscope to examine the biopharmaceutical company's molecules.

Cytokinetics, Incorporated (NASDAQ:CYTK)

Cytokinetics, Incorporated (NASDAQ:CYTK) is a late-stage pharmaceutical company committed to developing, commercializing, and discovering inhibitors and muscle activators. The financial research firm Stifel started analyst coverage of CYTK with a Buy rating due to its new promising drug, aficamten, promising an exciting couple of years ahead.

According to Stifel, aficamten is an extraordinary drug with a high competitive bar. Even outside the US, the drug is set to bring in millions of dollars of revenue for the company. In December, one of the company’s partners transferred the rights for the drug in China, Taiwan, and Hong Kong to Sanofi. Cytokinetics (NASDAQ:CYTK) is set to receive $150 million in a one-time payment and somewhere between $10-$20 million in sales. In Japan, the company has struck a similar deal with Bayer. In this way, Cytokinetics (NASDAQ:CYTK)can now focus on marketing the drug in the US while leaving its international operations to companies that have a better global presence.

The stock is down 43% in the last year, though that has a lot to do with Novartis walking away from an M&A deal. Apart from the promise of aficamten, new M&A activity cannot be ruled out and forms one of the components of Stifel’s bullish thesis on the stock.

Overall, CYTK ranks 10th on our list of stocks that analysts are talking about. While we acknowledge the potential of CYTK as a leading AI investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for an AI stock that is as promising as CYTK but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap

Disclosure: None. This article is originally published at Insider Monkey.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10